Study Title:
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35; IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents: A Groupwide Phase III Study
CIRB:
Lead Group:
Status:
Review Status: